Literature DB >> 20670857

Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma.

Yoshiaki Murakami1, Kenichiro Uemura, Takeshi Sudo, Yasuo Hayashidani, Yasushi Hashimoto, Akira Nakashima, Yoshio Yuasa, Naru Kondo, Hiroki Ohge, Taijiro Sueda.   

Abstract

BACKGROUND: This study evaluated the prognostic significance of the number of metastatic lymph nodes and the ratio of metastatic nodes to total number of examined lymph nodes (lymph node ratio, LNR) after resection of pancreatic carcinoma. STUDY
DESIGN: Records of 119 consecutive patients with pancreatic ductal carcinoma, who underwent R0 or R1 pancreatectomy with regional node dissection, were reviewed retrospectively. Clinical factors, pathologic factors including number of metastatic nodes and LNR, and survival were analyzed by univariate and multivariate analyses.
RESULTS: Overall survival rates were 78%, 28%, and 20% at 1, 3, and 5 years, respectively. The median numbers of evaluated lymph nodes and involved nodes were 28 and 3, respectively. Univariate analysis revealed that tumor location, postoperative adjuvant chemotherapy, tumor differentiation, choledochal invasion, portal or splenic vein invasion, extrapancreatic nerve plexus invasion, resection margin status, node status, number of involved nodes, LNR, International Union against Cancer (UICC) pT factor, and UICC stage correlated significantly (p < 0.05) with increased survival. By multivariate analysis, negative node metastasis (p = 0.008) and 0 or 1 involved node (p = 0.004), but not LNR, correlated independently with longer survival. The 1-, 3-, and 5-year survival rates of patients with 0 or 1 metastatic node and patients with 2 or more metastatic nodes were 91%, 48%, and 40% and 66%, 10%, and 0%, respectively.
CONCLUSIONS: The number of metastatic nodes, but not LNR, is one of the most powerful prognostic factors after resection of pancreatic carcinoma. Copyright 2010 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20670857     DOI: 10.1016/j.jamcollsurg.2010.03.037

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  53 in total

1.  Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.

Authors:  Chang Moo Kang; Yong Eun Chung; Jeong Youp Park; Jin Sil Sung; Ho Kyoung Hwang; Hye Jin Choi; Hyunki Kim; Si Young Song; Woo Jung Lee
Journal:  J Gastrointest Surg       Date:  2011-12-20       Impact factor: 3.452

Review 2.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

3.  Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.

Authors:  Peter J Allen; Deborah Kuk; Carlos Fernandez-Del Castillo; Olca Basturk; Christopher L Wolfgang; John L Cameron; Keith D Lillemoe; Cristina R Ferrone; Vicente Morales-Oyarvide; Jin He; Matthew J Weiss; Ralph H Hruban; Mithat Gönen; David S Klimstra; Mari Mino-Kenudson
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

4.  Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.

Authors:  Masayuki Sho; Takahiro Akahori; Toshihiro Tanaka; Shoichi Kinoshita; Minako Nagai; Satoshi Nishiwada; Tetsuro Tamamoto; Hideyuki Nishiofuku; Chiho Ohbayashi; Masatoshi Hasegawa; Kimihiko Kichikawa; Yoshiyuki Nakajima
Journal:  Langenbecks Arch Surg       Date:  2015-05-01       Impact factor: 3.445

5.  Current surgical management of pancreatic cancer.

Authors:  Charles B Kim; Shuja Ahmed; Eddy C Hsueh
Journal:  J Gastrointest Oncol       Date:  2011-09

6.  The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma.

Authors:  Wenchuan Wu; Jin He; John L Cameron; Martin Makary; Kevin Soares; Nita Ahuja; Neda Rezaee; Joseph Herman; Lei Zheng; Daniel Laheru; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss
Journal:  Ann Surg Oncol       Date:  2014-04-26       Impact factor: 5.344

7.  N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.

Authors:  Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2012-12-11       Impact factor: 3.452

8.  Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.

Authors:  Biku J John; Prashant Naik; Alastair Ironside; Brian R Davidson; Guiseppe Fusai; Roopinder Gillmore; Jennifer Watkins; Sakhawat H Rahman
Journal:  HPB (Oxford)       Date:  2013-01-14       Impact factor: 3.647

9.  International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.

Authors:  Stijn van Roessel; Gyulnara G Kasumova; Joanne Verheij; Robert M Najarian; Laura Maggino; Matteo de Pastena; Giuseppe Malleo; Giovanni Marchegiani; Roberto Salvia; Sing Chau Ng; Susanna W de Geus; Sanne Lof; Francesco Giovinazzo; Jacob L van Dam; Tara S Kent; Olivier R Busch; Casper H van Eijck; Bas Groot Koerkamp; Mohammed Abu Hilal; Claudio Bassi; Jennifer F Tseng; Marc G Besselink
Journal:  JAMA Surg       Date:  2018-12-19       Impact factor: 14.766

10.  Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle.

Authors:  Shaunagh McDermott; Sarah P Thayer; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Ralph Weissleder; Mukesh G Harisinghani
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.